IDWEEK 2016

Emerging Viruses: 'Any Outbreak, Anywhere in the World, Can Be a Threat, Everywhere'

By October 30, 2016

With international travel, "any outbreak, anywhere in the world can be a threat, everywhere." That's the reality of an increasingly connected world, said Malik Peiris, PhD, of the School of Public Health at the HKU-Pasteur Research Center, The University of Hong Kong, Pokfulam, Hong Kong, at IDWeek 2016.

Long-Term PPI Use Discouraged for HIV-1-Infected Patients

By October 30, 2016

Long-term use of proton pump inhibitors (PPIs) might increase microbial translocation and innate immune activation but not enterocyte turnover or T-cell activation among people infected with HIV-1, according to research findings reported at IDWeek 2016.

Promising Efficacy for Meningococcal Vaccine Candidate Among Adolescents

By October 30, 2016

GSK Vaccines' investigational meningococcal vaccine against serogroups A, B, C, W and Y (MenABCWY) is broadly effective among adolescents, according to the company's phase 2b, observer-blind, multicenter study, reported at IDWeek 2016.

Antiviral Activity of Elbasvir/Grazoprevir Unaffected by HIV/HBV Drugs

By October 30, 2016

HIV and hepatitis B virus (HBV) drugs had no impact on antiviral activity of grazoprevir or elbasvir, and neither agent affected HIV and HBV replication, a study presented at IDWeek has shown.

Depression and HIV Infection Shown to Increase Mortality Risk

By October 30, 2016

Together, depression and HIV infection are "strongly associated" with all-cause mortality in U.S. veterans, results from one of the largest analyses to date to examine this association reported at IDWeek 2016.

Which Antibiotics Up Risk of AKI in Pediatric Oncology Patients?

By October 30, 2016

In children with cancer, concurrent vancomycin and piperacillin-tazobactam administration may increase risk of acute kidney injury, a retrospective study presented at IDWeek has shown.

Is Extended-Interval Aminoglycoside Dosing Safe in Pediatric Patients?

By October 30, 2016

Extended-interval aminoglycoside dosing "appears of be safe in pediatric patients," a retrospective study presented at IDWeek has found.

Vit D Deficiency Common in Treatment-Naïve Patients with HIV

By October 30, 2016

Vitamin D deficiency is prevalent among treatment-naïve HIV-infected patients, researchers reported at IDWeek 2016.

Low Risk of Hepatic Decompensation With PrOD Regimen, Study Finds

By October 30, 2016

The overall risk of hepatic decompensation in patients treated with the paritaprevir/ritonavir, ombitasvir, dasabuvir (PrOD) regimen during and up to 12 weeks after completion of treatment was low, Adeel A. Butt, MD, MS, of the VA Pittsburgh Healthcare System, Pittsburgh, PA, told IDWeek 2016 attendees.

Missed Chances for Hep A, B Vaccinations Could Harm HCV/HIV Co-Infected Patients

By October 30, 2016

Opportunities to vaccinate against Hepatitis A virus were missed in more than half of patients with HIV and Hepatitis C virus co-infection, researchers reported at IDWeek 2016.

Hepatic Safety of Modern ART Regimens for HIV Confirmed

By October 30, 2016

Use of protease inhibitors was associated with higher rates of liver aminotransferase elevations in patients with HIV; however, severe acute liver injury was uncommon with all antiretroviral therapy (ART) regimens, concluded a retrospective cohort study presented at IDWeek 2016.

For <i>S. maltophilia</i> Infections, Consider Minocycline Monotherapy

By October 30, 2016

Minocycline "may be a good choice" for infections caused by Stenotrophomonas maltophilia, "an inherently resistant organism with limited treatment options," concluded authors of a retrospective study presented at IDWeek.

High Real-World SVR Rates for LDV/SOF in HCV/HIV Co-Infected Patients

By October 29, 2016

Overall sustained virologic response (SVR) rate for ledipasvir/sofosbuvir in hepatitis C virus (HCV)/HIV co-infected patients in real world settings was 95.2%.

Imipenem-Relebactam Shows Strong Potential Against Respiratory Pathogens

By October 29, 2016

Relebactam (MK-7655) restored imipenem activity against many respiratory tract infection isolates from the US and Canada, researchers reported at IDWeek 2016.

High Efficacy With Sofosbuvir/Velpatasvir + Voxilaprevir for Pangenotypic HCV

By October 29, 2016

For patients with hepatitis C virus (HCV) infection genotype (GT) 1-6, treatment with sofosbuvir/velpatasvir plus voxilaprevir (GS-9857) once daily was safe, well tolerated, and highly effective in treatment-naive and treatment-experienced patients, reported Ronald Nahass, MD, FIDSA, FSHEA, from ID Care, Inc., Hillsborough, NJ, at IDWeek 2016.

Delafloxacin vs. Vancomycin Compared for ABSSSI Treatment

By October 29, 2016

An age- and gender-based pooled analysis presented at IDWeek 2016 showed that delafloxacin had comparable outcomes to vancomycin at 48-72 hours for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

Cabotegravir Well-Tolerated for HIV Infection, Meta-Analysis Shows

By October 29, 2016

The investigational anti-HIV integrase inhibitor cabotegravir (CAB) is well-tolerated, according to a meta-analysis of clinical trial data reported at IDWeek 2016.

TMP-SMX, Clindamycin Shown to Improve Abscess Cure Rates

By October 29, 2016

Trimethoprim-sulfamethoxazole (TMP-SMX) or clindamycin treatment following small abscess incision and drainage (I&D) improves outcomes.

Is AKI Incidence Higher With Levofloxacin or Piperacillin/Tazobactam?

By October 29, 2016

A total of 2,538 patients taking piperacillin/tazobactam and 1,134 patients taking levofloxacin were included in the analysis.

Two MMR Vaccines Compared in Phase 3 Non-Inferiority Trial

By October 29, 2016

GSK's investigational combined measles, mumps, and rubella (MMR) vaccine (GSK_MMR) "demonstrated an acceptable immune response" that was non-inferior to Merck's MMR vaccine (MRK_MMR), a multinational, randomized, Phase 3A, controlled, observer-blinded study reported at IDWeek 2016 has shown.

Antivirals Underutilized in Children With Outpatient Influenza-Like Illness

By October 29, 2016

Children presenting with outpatient influenza-like illness rarely received an antiviral prescription, according to a retrospective cohort study presented at IDWeek 2016.

Daily Dolutegravir + Rilpivirine Safe for Previously-Treated HIV Patients

By October 29, 2016

Combined daily dolutegravir (DTV, 50 mg) and rilpivirine (RPV, 25 mg) is safe for HIV-infected patients previously treated with other regimens, according to findings from a small observational retrospective study reported at IDWeek 2016.

Investigational Herpes Zoster Vaccine Improves QoL in Older Adults

By October 29, 2016

An investigational herpes zoster subunit vaccine significantly reduces disease risk as well as severity in those who develop breakthrough disease in adults 50 years and older

ADHD, SIDS, and Vaccines: What's the Link?

By October 29, 2016

Population level-analyses between 2003-2013 found no links between sudden infant death syndrome (SIDS), attention-deficit/hyperactivity disorder (ADHD), and vaccines, Jana Shaw, MD, MPH, Associate Professor of Pediatrics, Pediatric Infectious Diseases, Upstate Golisano Children's Hospital, State University of New York, Syracuse, NY, presented at IDWeek 2016.

Delafloxacin Comparable to Vancomycin/Aztreonam for Acute Skin Infections

By October 29, 2016

Intravenous and oral delafloxacin (DLX) monotherapy, an investigational, full-spectrum anionic fluoroquinolone, exhibits tolerability and efficacy comparable to those for vancomycin/aztreonam (VAN/AZ) among adult patients with acute bacterial and skin structure infections (ABSSSI), including MRSA and gram-negative infections.

Is One-Pill ART Superior to Multi-Pill Regimens Among HIV-Infected Youth?

By October 29, 2016

Compared to multi-pill antiretroviral therapy (ART), 1-pill ART is associated with improved likelihoods of initial and sustained virologic suppression among HIV-positive young people, according to findings from a retrospective multiinstitutional analysis reported at IDWeek 2016.

High-Dose Flu Vaccine Reduces Hospitalization Risk in Long-Term Care Residents

By October 29, 2016

During the 2013-2014 A/H1N1 dominant flu season, Fluzone High-Dose vaccine reduced the risks of all-cause hospitalization and hospitalization for respiratory conditions among long-term care residents compared with Fluzone standard-dose vaccine, investigators reported at IDWeek.

Live, Attenuated Influenza Vaccine Safe in Children with Asthma

By October 28, 2016

Concerns about administering live, attenuated influenza vaccine (LAIV) in children with asthma "may not be warranted," concluded authors of a study presented at IDWeek.

Posaconazole Prophylaxis Safe in Routine Clinical Use for Hematological Malignancies

By October 28, 2016

Both the tablet and intravenous (IV) formulations of posaconazole appeared to be safe and effective for primary prophylaxis against invasive fungal infections in patients with hematologic malignancies, according to results of a retrospective cohort study presented at IDWeek 2016.

ICU overprescribing of Antibiotics for CAP Still a Problem

By October 28, 2016

Antibiotics overprescribing for patients with community-acquired pneumonia is a persisting and significant problem in the ICU, researchers reported at IDWeek 2016.